{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T14:23:33Z","timestamp":1766413413614,"version":"3.48.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T00:00:00Z","timestamp":1753488000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.gore.2025.101816","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T06:13:51Z","timestamp":1753683231000},"page":"101816","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Pembrolizumab-associated Guillain-Barre syndrome in a patient with endometrial cancer: A case report"],"prefix":"10.1016","volume":"60","author":[{"given":"Emily","family":"Gleason","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0100-337X","authenticated-orcid":false,"given":"Meridith","family":"Pollie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjana","family":"Satish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sue","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janos L.","family":"Tanyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.gore.2025.101816_b0005","doi-asserted-by":"crossref","first-page":"631","DOI":"10.3390\/cancers14030631","article-title":"Overview of immune checkpoint inhibitors in gynecological cancer treatment","volume":"14","author":"Pir\u0161","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.gore.2025.101816_b0010","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","article-title":"The PD\u20101 pathway in tolerance and autoimmunity","volume":"236","author":"Francisco","year":"2010","journal-title":"Immunol. Rev."},{"issue":"4","key":"10.1016\/j.gore.2025.101816_b0015","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"7","key":"10.1016\/j.gore.2025.101816_b0020","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1200\/JCO.21.01874","article-title":"Pembrolizumab in patients with microsatellite instability\u2013high advanced endometrial cancer: results from the KEYNOTE-158 study","volume":"40","author":"O\u2019Malley","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.gore.2025.101816_b0025","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.gore.2025.101816_b0030","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.gore.2025.101816_b0035","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1186\/s12967-020-02523-5","article-title":"A phase 2 study of combined chemo-immunotherapy with cisplatin-pembrolizumab and radiation for unresectable vulvar squamous cell carcinoma","volume":"18","author":"Yeku","year":"2020","journal-title":"J. Transl. Med."},{"issue":"16_suppl","key":"10.1016\/j.gore.2025.101816_b0040","doi-asserted-by":"crossref","first-page":"TPS5617","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS5617","article-title":"ENGOT-ov65\/KEYNOTE-B96: phase 3, randomized, double-blind study of pembrolizumab versus placebo plus paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer","volume":"40","author":"Colombo","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.gore.2025.101816_b0045","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.gore.2025.101816_b0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: review of the literature","volume":"73","author":"Cuzzubbo","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"7","key":"10.1016\/j.gore.2025.101816_b0055","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/CJI.0000000000000364","article-title":"Immune checkpoint inhibitor\u2013related Guillain-Barr\u00e9 syndrome: a case series and review of the literature","volume":"44","author":"Janssen","year":"2021","journal-title":"J. Immunother."},{"key":"10.1016\/j.gore.2025.101816_b0060","article-title":"Guillain-Barre syndrome in a patient with uterine adenocarcinoma undergoing treatment with immune-checkpoint inhibitor therapy: a case report and review of the literature","volume":"36","author":"Brzezinska","year":"2021","journal-title":"Gynecol. Oncol. Rep."},{"issue":"11","key":"10.1016\/j.gore.2025.101816_b0065","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41582-019-0250-9","article-title":"Diagnosis and management of Guillain\u2013Barr\u00e9 syndrome in ten steps","volume":"15","author":"Leonhard","year":"2019","journal-title":"Nat. Rev. Neurol."},{"issue":"36","key":"10.1016\/j.gore.2025.101816_b0070","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.gore.2025.101816_b0075","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2023-000544","article-title":"Guillain-Barr\u00e9 syndrome and checkpoint inhibitor therapy: insights from pharmacovigilance data","volume":"6","author":"Abrahao","year":"2024","journal-title":"BMJ Neurol. Open"},{"key":"10.1016\/j.gore.2025.101816_b0080","first-page":"1","article-title":"Safe transition to pembrolizumab following ipilimumab-induced Guillain-Barr\u00e9 syndrome: a case report and review of the literature","volume":"2019","author":"Gravbrot","year":"2019","journal-title":"Case Rep. Oncol. Med."},{"issue":"1","key":"10.1016\/j.gore.2025.101816_b0085","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000504930","article-title":"Treatment considerations for patients with unresectable metastatic melanoma who develop pembrolizumab-induced Guillain-Barr\u00e9 toxicity: a case report","volume":"13","author":"Muralikrishnan","year":"2020","journal-title":"Case Rep. Oncol."},{"issue":"6","key":"10.1016\/j.gore.2025.101816_b0090","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1212\/WNL.61.6.736","article-title":"Practice parameter: immunotherapy for Guillain\u2013Barr\u00e9 syndrome","volume":"61","author":"Hughes","year":"2003","journal-title":"Neurology"}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578925001419?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578925001419?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T14:20:00Z","timestamp":1766413200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578925001419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":18,"alternative-id":["S2352578925001419"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2025.101816","relation":{},"ISSN":["2352-5789"],"issn-type":[{"type":"print","value":"2352-5789"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pembrolizumab-associated Guillain-Barre syndrome in a patient with endometrial cancer: A case report","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2025.101816","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101816"}}